不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel：ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
弥漫大 B 细胞淋巴瘤中抗 CD19 治疗的序贯：从机制洞察到临床策略
英文原题：Sequencing Anti-CD19 Therapies in Diffuse Large B-Cell Lymphoma: From Mechanistic Insights to Clinical Strategies.
查看英文原题
Sequencing Anti-CD19 Therapies in Diffuse Large B-Cell Lymphoma: From Mechanistic Insights to Clinical Strategies.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
包括单克隆抗体、抗体药物偶联物和嵌合抗原受体（CAR）T细胞产品在内的CD19靶向疗法，显著改善了复发/难治性弥漫大B细胞淋巴瘤（R/R DLBCL）的治疗结局。尽管临床疗效确切，耐药和抗原调节仍构成重大挑战，尤其是需要序贯治疗的患者。本综述全面介绍CD19生物学及其作为治疗靶点的意义。我们考察抗原丢失、表位遮蔽和T细胞耗竭等耐药机制，以及肿瘤微环境免疫抑制的影响。未来工作应优先整合流式细胞术、免疫组织化学和转录组分析等实时诊断，以及AI辅助预测模型，以优化治疗序贯方案并扩大个体化免疫治疗的可及性。
展开英文摘要原文
CD19-targeted therapies, including monoclonal antibodies, antibody-drug conjugates, and chimeric antigen receptor (CAR) T-cell products, have significantly improved outcomes in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). Despite their clinical efficacy, resistance and antigen modulation pose substantial challenges, especially in patients requiring sequential therapy. This review provides a comprehensive overview of CD19 biology and its relevance as a therapeutic target.
We examine mechanisms of resistance such as antigen loss, epitope masking, and T-cell exhaustion, as well as the implications of tumor microenvironmental immunosuppression. Future efforts should prioritize the integration of real-time diagnostics, such as flow cytometry, immunohistochemistry, and transcriptomic profiling, and AI-assisted predictive models to optimize therapeutic sequencing and expand access to personalized immunotherapy.
论文信息
- 作者
- Laddaga FE、Della Mura M、Sorino J、Caruso A、Martinotti S、Ingravallo G、Gaudio F
- 第一作者单位
- Hematology and Cell Therapy Unit, IRCCS Istituto Tumori "Giovanni Paolo II", 70124 Bari, Italy.Italy
- 通讯作者单位
- Department of Medicine and Surgery, LUM University "Giuseppe Degennaro", Casamassima, 70010 Bari, Italy.Italy
- 文献类型
- 综述
- 期刊
- International journal of molecular sciences2025 Sep 5
- 原文标识
- PubMed 40943582 · DOI 10.3390/ijms26178662
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →